Antiplatelet therapy with<unk>  is a mainstay of pharmacotherapy in STEMI. In the International Study of Infarct Survival 2 (ISIS 2),<unk>  reduced mortality in STEMI as much as streptokinase (by approximately 25%) when compared to the administration of neither agent.   Full doses of non-enteric coated<unk>  should be administered as soon as possible to patients with STEMI if there are no contraindications.
ST elevation myocardial infarction aspirin therapy
ST elevation myocardial infarction anticoagulant and antithrombotic therapy
ST elevation myocardial infarction fibrinolytic therapy
ST elevation myocardial infarction calcium channel blocker therapy
ST elevation myocardial infarction nitrate therapy
ST elevation myocardial infarction thienopyridine therapy
Unstable angina / non ST elevation myocardial infarction anticoagulant therapy
ST elevation myocardial infarction beta blocker therapy